Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)

Antiviral Therapy

Volumn 11, Issue 7, 2006, Pages 889-899

  Launay, Odile ^a,b   Duval, Xavier ^a,c   Dalban, Cécile ^d,e   Descamps, Diane ^c   Peytavin, Gilles ^c   Certain, Agnès ^c   Mouajjah, Saïd ^d,e   Ralaimazava, Pascal ^c   Verdon, Renaud ^f   Costagliola, Dominique ^d,e   Clavel, François ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b AP HP ^*  (France)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG INHIBITION; FEMALE; FOLLOW UP; GENOTYPE; HEART INFARCTION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IC 50; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; ENDPOINT DETERMINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; PILOT PROJECTS; RITONAVIR; SPECIES SPECIFICITY; VIRAL LOAD;

EID: 33750937361     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
2. Costagliola D, Potard V, Duvivier C, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther 2005; 10:563-573.
3. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953
4. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-1335.
5. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and GagPol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72:3300-3306.
6. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7:712-718.
7. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000; 49:41-66.
8. Decks S G, Hoh R, Neilands T B, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537-1544.
9. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-242.
10. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
11. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-1647.
12. Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-985.
13. Kousignian I, Abgrall S, Grabar S, et al. Effect of HAART, CD4 cell counts, and viral load on incidence of AIDS-defining events. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, USA. Abstract 592.
14. HIV-1 genotypic drug resistance interpretation algorithms, Table of rules 2002 [3 tables on the Internet]. Available from: http://hivfrenchresistance. org/tab2002.html
15. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
16. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
17. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995; 692:45-52.
18. King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS 2005; 19:1059-1063.
19. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-11112.
20. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
21. Decks SG, Wrin T, Liegler T, et al. Virologic and immunologie consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
22. Ruff CT, Ray SC, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002; 76:9481-9492.
23. Boucher C A, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37:2231-2234.